Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

Clinical trial NCT06939127 · RECRUITING

Trial details

NCT number: NCT06939127
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)

Start date: 2025-04-01
Primary completion: 2026-05-31
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.